receptores de antígenos quiméricos de células t (car t-cells)£o regional... · chimeric antigen...
TRANSCRIPT
![Page 1: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/1.jpg)
Vanderson Rocha, MD, PhD
Professor de Hematologia, Hemoterapia e Terapia Celular–
Diretor da Fundação Pro-sangue
Universidade de São Paulo
Receptores de antígenos quiméricos de
células T (CAR T-cells)
![Page 2: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/2.jpg)
Terapia ‘CAR’
![Page 3: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/3.jpg)
![Page 4: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/4.jpg)
CAR-T Cell
• Overview of the concept of CAR-T Cell therapy
• Current evidence and practical issues in the application of CAR-T cell therapy for the management of:
- ALL
- Lymphoma
- AML
- MM
- Solid tumors
![Page 5: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/5.jpg)
Acute Lymphoblastic Leukemia–
Potential Cell-Therapy Targets
![Page 6: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/6.jpg)
CD19: An ideal target
![Page 7: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/7.jpg)
![Page 8: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/8.jpg)
CAR-T cell
![Page 9: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/9.jpg)
Current Chimeric Antigen
Receptors T-Cell in Clinical Trials
![Page 10: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/10.jpg)
![Page 11: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/11.jpg)
Chimeric antigen receptor (CAR) technology
Reprogramming a patient’s T cells to “hunt” and destroy cancer
MOA data is based on in vitro/in vivo data. Clinical benefit is unknown
CTL019 is an investigational compound. Efficacy and safety have not been established. There is no guarantee that CTL019 will become commercially available.
The reprogrammed T cells are expanded in the manufacturing facility.
4
The reprogrammed T cells are reintroduced into the patient’s
blood.
ReprogrammedT cells
6
The patient receives lymphodepletingchemotherapy to reduce the level of white blood cells and help the body accept the
reprogrammed T cells.
Lymphodepletingchemotherapy 5
White blood cells, including T cells, are separated from the patient’s blood in a process
called leukapheresis. They are then sent to a manufacturing facility for reprogramming.
T-cell
1
Ex vivo, in a manufacturing facility, genes encoded to
recognize specific cancer cells are transferred into the patient’s
T cells using an inactive virus (viral vector).
2
Inactiveviral
vector
Within the patient’s body, the T cells expand. The CTL019 cells “hunt” cancer cells expressing CD19,
attach to them, and initiate direct cell death.
Cancercell
CLT019
CTL019 attaches to cancer cells
Cancer cell death is initiated
7
Once the gene transfer is complete, T cells are now reprogrammed to “hunt”
cancer cells by expressing a CAR on its surface. For CTL019, the T cell is
programmed to hunt the CD19 protein on the surface of B cells.
3CLT019
![Page 12: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/12.jpg)
CAR T-cells
http://www.bloodjournal.org/content/118/18/4761.full?sso-checked=true
1) Coleta de células T
do doador
3. integraçãocom DNA da cél.
2) Infecção das células
T pelo vetor viral
1. ligação
2. fusão
4. leitura do DNA inserido e formação de
novas proteínas(receptores)
5. Inserção dos receptoresna membrana da célula
4) Monitorização do
paciente
a) Resposta da doenca:
• Tomografia
• Biópsia de medula óssea/
• Citometria de fluxo
b) Persistência das CAR T-
cells:
• imunohistoquimica de
biópsia de medula óssea
• Reação de PCR (biologia
molecular) e citometria
de fluxo
3) Transferência da
célula T adaptada
para o paciente
+/-
Lymphodepleting
conditioning
CD3
Cel T
![Page 13: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/13.jpg)
Patient Stabilization
![Page 14: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/14.jpg)
Lymphodepleting Chemoterapy
![Page 15: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/15.jpg)
CAR T cells na LLA crianças
![Page 16: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/16.jpg)
![Page 17: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/17.jpg)
![Page 18: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/18.jpg)
![Page 19: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/19.jpg)
*Tisagenlecleucel
NEJM 2018
![Page 20: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/20.jpg)
EBMT 2018
![Page 21: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/21.jpg)
![Page 22: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/22.jpg)
![Page 23: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/23.jpg)
ELIANA: CTL019 (tisagenlecleucel)
• Single arm, global study 25 sites in 11 countries across North America, Europe, Australia and Asia
Maude et al NEJM 2018:378:439-448
![Page 24: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/24.jpg)
Duration of response and relapse-Free Survival
![Page 25: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/25.jpg)
ELIANA: Overall Survival
![Page 26: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/26.jpg)
![Page 27: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/27.jpg)
Toxicity
• Cytokine Release Syndrome (CRS)
- Correlates with T cell proliferation and efficacy
- Severity related to disease burden
- Observed in 88%; 27% requiered CTI support
- Reversed with novel approach – cytokine blockade
• Neurotoxicity
- Seen in several CD19 immunotherapy trials: NCI, CHOP/UPenn/ MSKCC
• Chronic B cell aplasia requiring Ig replacement
• Macrophage activating syndrome
![Page 28: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/28.jpg)
Neelapu SS et al Nat Rev Clin Oncol 2018:15:47-62
![Page 29: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/29.jpg)
Cytokine Release Syndrome
![Page 30: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/30.jpg)
Severe CRS management
• Supportive Care
- Vasopressor, O2, ventilation, Blood products (FFP, cryo)
• Lympholytics
- Steroids tried with some effect but potencial to reduceefficacy
• Cytokine-directed therapy
- IL-6 noted to be very elevated
- Anti-IL-6 therapy highly effective with no apparenteffect on efficacy
![Page 31: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/31.jpg)
Tocilizumab
• IL-6 receptor antagonist
- Block IL-6 mediated effects
- Indicated in: juvenile idiopathic arthritis, Rheumatoid arthritis; now indicated por CRS treatment(aug 30,2017)
- Rare side effects of transaminitis and neutropenia
Grupp et al NEJM 2013:368:1509-1518
![Page 32: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/32.jpg)
![Page 33: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/33.jpg)
Current labeled indications for CTL019
• ALL up to age 25 years
• Refractory or second relapse
Other key points:
• No donor required
• Not is necessary the patients be in complete remission to receive treatment
• There is a plan for a registry
www.pharma.us.Novartis.com/files/kymriah.pdf- feb 13,2018
![Page 34: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/34.jpg)
Mechanisms of Relapse
![Page 35: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/35.jpg)
Gardner et al ASH 2017 Abstract 219
![Page 36: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/36.jpg)
Shah BD et al ASCO 2017 Abstract 3024
![Page 37: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/37.jpg)
CAR T cells nos Linfomas
![Page 38: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/38.jpg)
![Page 39: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/39.jpg)
Phase 2 ZUMA 1: KTE-019 (AxicabtageneCiloleucel) in Refractory Aggressive NHL
Neelapu SS et al NEJM 2017:377:2531-2544
![Page 40: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/40.jpg)
Phase 2 Zuma-1
![Page 41: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/41.jpg)
Phase 2 ZUMA 1
• Adverse effects:
– Grade 5 AEs in 3 patients: but drug related 2 events (1 HLH and 1 cardiac arrestin the setting of CRS)
– Grade >3 AEs: CRS (13%) , Neurologic events (28%)
• Special considerations:
– Use a lymphodepleting regimen of Cy and fludarabine before infusion; premedicate with acetaminophen and a H1-antihistamine
– Treat severe CRS with tocilizumab and corticosteroids
– Do not administer to patients with active infection or inflammatory disorders
– Target dose 2x106 (maximum 2x108) CAR-positive viable T cells per Kg bodyweight
Neelapu SS et al NEJM 2017:377:2531-2544
![Page 42: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/42.jpg)
![Page 43: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/43.jpg)
![Page 44: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/44.jpg)
![Page 45: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/45.jpg)
![Page 46: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/46.jpg)
![Page 47: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/47.jpg)
![Page 48: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/48.jpg)
Patient Case: Ongoing 9+ mo Durable CR in Refractory DLBCL
Baseline Day 90
• 62-yo M with DLBCL
• Prior therapies- R-CHOP
- R-GDP
- R-ICE
- R-lenalidomide
• No response to last 3 lines of therapy
48Neelapu & Locke et al ASH 2016, #LBA-6
![Page 49: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/49.jpg)
![Page 50: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/50.jpg)
![Page 51: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/51.jpg)
CAR T cells na LMA
![Page 52: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/52.jpg)
CD123-Specific CAR T Cells
• Phase 1
• 6 pts with relapsed AML following HCT received CD123-Specific CAR T cells
• 2 pts on dose level 1 (50M CAR+ T): 1 CR
• 4 pts on dose level 2 (200M CAR+ T: 1 CR + 1 sustained CR and 2 pts achieving reduction of marrow blasts
• No DLT or treatment-related cytopenias
Budd et al., Blood 2017;130:811
![Page 53: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/53.jpg)
CD33-specific CAR T cells
• Results still at case report level.
• Transient effect on blasts.
• Ongoing trials in AML:
NCT # (recruting) Phase Site
NCT01864902 1/2 China
NCT02958397 1/2 China
NCT03126864 1 US (MDACC)
NCT03222674 1/2 China
![Page 54: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/54.jpg)
CAR T cells no Mieloma
![Page 55: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/55.jpg)
![Page 56: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/56.jpg)
![Page 57: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/57.jpg)
GHOSH ET AL. Leukemia & Lymphoma 2017
![Page 58: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/58.jpg)
CAR T cells nos tumores sólidos
![Page 59: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/59.jpg)
Anti-solid tumor T-cells
Problems/Issues with CAR or TCR treatment of solid
tumors
Cross reaction – potentially lethal off-target/off-tissue cell
killing
Currently poorly effective against solid tumors
Immunosuppressive microenvironment
Low efficacy, low persistence
![Page 60: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/60.jpg)
Yong C , Immunology and Cell Biology 2017
![Page 61: Receptores de antígenos quiméricos de células T (CAR T-cells)£o Regional... · Chimeric antigen receptor (CAR) technology Reprogramming a patient’s T cells to “hunt” and](https://reader031.vdocuments.net/reader031/viewer/2022011807/5c491b6893f3c3521c592f9c/html5/thumbnails/61.jpg)
Yong C , Immunology and Cell Biology 2017